- Home
- Publications
- Publication Search
- Publication Details
Title
Drug resistance and new therapies in colorectal cancer
Authors
Keywords
-
Journal
WORLD JOURNAL OF GASTROENTEROLOGY
Volume 24, Issue 34, Pages 3834-3848
Publisher
Baishideng Publishing Group Inc.
Online
2018-09-14
DOI
10.3748/wjg.v24.i34.3834
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tight Junction Protein Claudin-2 Promotes Self-Renewal of Human Colorectal Cancer Stem-like Cells
- (2018) Sophie Paquet-Fifield et al. CANCER RESEARCH
- Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics
- (2018) Femke M. de Man et al. CLINICAL PHARMACOKINETICS
- Immune checkpoint blockade combined with IL-6 and TGF-β inhibition improves the therapeutic outcome of mRNA-based immunotherapy
- (2018) Lukasz Bialkowski et al. INTERNATIONAL JOURNAL OF CANCER
- Eradication of spontaneous malignancy by local immunotherapy
- (2018) Idit Sagiv-Barfi et al. Science Translational Medicine
- Implications of ABCG2 Expression on Irinotecan Treatment of Colorectal Cancer Patients: A Review
- (2017) Dorte Lisbet Nielsen et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Efficacy and safety of atezolizumab (atezo) and bevacizumab (bev) in a phase Ib study of microsatellite instability (MSI)-high metastatic colorectal cancer (mCRC).
- (2017) Howard S. Hochster et al. JOURNAL OF CLINICAL ONCOLOGY
- Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment
- (2017) James L. Gulley et al. JNCI-Journal of the National Cancer Institute
- Tumour-associated macrophages as treatment targets in oncology
- (2017) Alberto Mantovani et al. Nature Reviews Clinical Oncology
- Prediction of novel target genes and pathways involved in irinotecan-resistant colorectal cancer
- (2017) Precious Takondwa Makondi et al. PLoS One
- Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial
- (2017) Estela Pineda et al. TUMOR BIOLOGY
- Transforming growth factor-β1 contributes to oxaliplatin resistance in colorectal cancer via epithelial to mesenchymal transition
- (2017) Liang Mao et al. Oncology Letters
- Expression of the cancer stem cell markers ABCG2 and OCT-4 in right-sided colon cancer predicts recurrence and poor outcomes
- (2017) Jun Hu et al. Oncotarget
- WBSCR22 confers oxaliplatin resistance in human colorectal cancer
- (2017) Dongmei Yan et al. Scientific Reports
- Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment
- (2017) James L. Gulley et al. JNCI-Journal of the National Cancer Institute
- Tumor-associated macrophages and response to 5-fluorouracil adjuvant therapy in stage III colorectal cancer
- (2017) Alberto Malesci et al. OncoImmunology
- A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer
- (2016) Tae Won Kim et al. BRITISH JOURNAL OF CANCER
- Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen
- (2016) Emeric Limagne et al. CANCER RESEARCH
- Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G
- (2016) Kohei Shitara et al. CANCER SCIENCE
- MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
- (2016) Peter J.R. Ebert et al. IMMUNITY
- Suppression of TWIST1 enhances the sensitivity of colon cancer cells to 5-fluorouracil
- (2016) Monika Sakowicz-Burkiewicz et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Epigenetic changes in histone acetylation underpin resistance to the topoisomerase I inhibitor irinotecan
- (2016) Cornelia Meisenberg et al. NUCLEIC ACIDS RESEARCH
- Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells
- (2016) E. J. Brea et al. Cancer Immunology Research
- Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy
- (2016) Rikke B. Holmgaard et al. OncoImmunology
- Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study
- (2015) Pilar Garcia-Alfonso et al. BMC CANCER
- PTX3 Is an Extrinsic Oncosuppressor Regulating Complement-Dependent Inflammation in Cancer
- (2015) Eduardo Bonavita et al. CELL
- Extent and Location of Tumor-Infiltrating Lymphocytes in Microsatellite-Stable Colon Cancer Predict Outcome to Adjuvant Active Specific Immunotherapy
- (2015) A. W. Turksma et al. CLINICAL CANCER RESEARCH
- Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer
- (2015) M. Peeters et al. CLINICAL CANCER RESEARCH
- The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4
- (2015) L. Liu et al. CLINICAL CANCER RESEARCH
- FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study
- (2015) Klaus Kaczirek et al. Clinical Colorectal Cancer
- Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis
- (2015) Filippo Pietrantonio et al. EUROPEAN JOURNAL OF CANCER
- A new way to target p53-defective colorectal cancer
- (2015) Yunhua Liu et al. Future Oncology
- Thymidylate synthase expression in circulating tumor cells: A new tool to predict 5-fluorouracil resistance in metastatic colorectal cancer patients
- (2015) Emne Ali Abdallah et al. INTERNATIONAL JOURNAL OF CANCER
- CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages
- (2015) Takanori Kitamura et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Jin Li et al. LANCET ONCOLOGY
- TP53 loss creates therapeutic vulnerability in colorectal cancer
- (2015) Yunhua Liu et al. NATURE
- Stromal gene expression defines poor-prognosis subtypes in colorectal cancer
- (2015) Alexandre Calon et al. NATURE GENETICS
- Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy
- (2015) A. Sivan et al. SCIENCE
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
- (2015) M. Vetizou et al. SCIENCE
- Targeting the tumor microenvironment to enhance antitumor immune responses
- (2015) Kevin Van der Jeught et al. Oncotarget
- Microbiota disbiosis is associated with colorectal cancer
- (2015) Zhiguang Gao et al. Frontiers in Microbiology
- Intratumoral delivery of mRNA: Overcoming obstacles for effective immunotherapy
- (2015) Kevin Van der Jeught et al. OncoImmunology
- Phenotyping of tumor-associated macrophages in colorectal cancer: Impact on single cell invasion (tumor budding) and clinicopathological outcome
- (2015) Viktor H. Koelzer et al. OncoImmunology
- Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity
- (2015) Kevin Van der Jeught et al. Oncotarget
- Tumour microenvironment of both early- and late-stage colorectal cancer is equally immunosuppressive
- (2014) A O'Toole et al. BRITISH JOURNAL OF CANCER
- Colorectal cancer statistics, 2014
- (2014) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Targeting the Tumor Microenvironment with Interferon-β Bridges Innate and Adaptive Immune Responses
- (2014) Xuanming Yang et al. CANCER CELL
- Microbes, Microbiota, and Colon Cancer
- (2014) Cynthia L. Sears et al. Cell Host & Microbe
- Colorectal Cancer Stem Cells: From the Crypt to the Clinic
- (2014) Ann Zeuner et al. Cell Stem Cell
- Intratumoral Immunization: A New Paradigm for Cancer Therapy
- (2014) A. Marabelle et al. CLINICAL CANCER RESEARCH
- Bacteroides fragilis subverts mucosal biology: from symbiont to colon carcinogenesis
- (2014) Cynthia L. Sears et al. JOURNAL OF CLINICAL INVESTIGATION
- PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer
- (2014) Lee S. Schwartzberg et al. JOURNAL OF CLINICAL ONCOLOGY
- FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
- (2014) Volker Heinemann et al. LANCET ONCOLOGY
- Clinical and Cellular Roles for TDP1 and TOP1 in Modulating Colorectal Cancer Response to Irinotecan
- (2014) C. Meisenberg et al. MOLECULAR CANCER THERAPEUTICS
- Immune Modulation in Cancer with Antibodies
- (2013) David B. Page et al. Annual Review of Medicine
- Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment
- (2013) Aleksandar D. Kostic et al. Cell Host & Microbe
- Fusobacterium nucleatum Promotes Colorectal Carcinogenesis by Modulating E-Cadherin/β-Catenin Signaling via its FadA Adhesin
- (2013) Mara Roxana Rubinstein et al. Cell Host & Microbe
- PIK3CA, BRAF , and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17
- (2013) Christos S. Karapetis et al. CLINICAL CANCER RESEARCH
- Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen-Specific T-cell Immunity in Head and Neck Cancer Patients
- (2013) R. M. Srivastava et al. CLINICAL CANCER RESEARCH
- Immune classification of colorectal cancer patients: impressive but how complete?
- (2013) Constantin N Baxevanis et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- The MAPK Pathway Is a Predominant Regulator of HLA-A Expression in Esophageal and Gastric Cancer
- (2013) K. Mimura et al. JOURNAL OF IMMUNOLOGY
- Colorectal cancer
- (2013) Hermann Brenner et al. LANCET
- Bcl-2/Bcl-xL Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models
- (2013) N. Tan et al. MOLECULAR CANCER THERAPEUTICS
- Cancer Immunotherapy
- (2013) J. Couzin-Frankel SCIENCE
- Microsatellite instability has a positive prognostic impact on stage II colorectal cancer after complete resection: results from a large, consecutive Norwegian series
- (2012) M. A. Merok et al. ANNALS OF ONCOLOGY
- Dependency of Colorectal Cancer on a TGF-β-Driven Program in Stromal Cells for Metastasis Initiation
- (2012) Alexandre Calon et al. CANCER CELL
- Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
- (2012) Douglas Hanahan et al. CANCER CELL
- Induction of cancer cell stemness by chemotherapy
- (2012) Xingwang Hu et al. CELL CYCLE
- T cell subsets and colorectal cancer: Discerning the good from the bad
- (2012) Martin Scurr et al. CELLULAR IMMUNOLOGY
- The association between two polymorphisms in the TS gene and risk of cancer: A systematic review and pooled analysis
- (2012) Jue-Yu Zhou et al. INTERNATIONAL JOURNAL OF CANCER
- Association ofKRASG13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab
- (2012) Sabine Tejpar et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapeutic Potential of Amanitin-Conjugated Anti-Epithelial Cell Adhesion Molecule Monoclonal Antibody Against Pancreatic Carcinoma
- (2012) Gerhard Moldenhauer et al. JNCI-Journal of the National Cancer Institute
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- Inhibition of Dendritic Cell Maturation by the Tumor Microenvironment Correlates with the Survival of Colorectal Cancer Patients following Bevacizumab Treatment
- (2012) A. J. Michielsen et al. MOLECULAR CANCER THERAPEUTICS
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic Significance of Tumor-Associated Macrophages in Solid Tumor: A Meta-Analysis of the Literature
- (2012) Qiong-wen Zhang et al. PLoS One
- Trial watch
- (2012) Laura Senovilla et al. OncoImmunology
- Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition
- (2011) K. P. Hoeflich et al. CANCER RESEARCH
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Methylation of Cancer-Stem-Cell-Associated Wnt Target Genes Predicts Poor Prognosis in Colorectal Cancer Patients
- (2011) Felipe de Sousa E Melo et al. Cell Stem Cell
- Epidermal Growth Factor Receptor Inhibition Augments the Expression of MHC Class I and II Genes
- (2011) B. P. Pollack et al. CLINICAL CANCER RESEARCH
- Pharmacokinetic and Metabolism Determinants of Fluoropyrimidines and Oxaliplatin Activity in Treatment of Colorectal Patients
- (2011) Antonio Gnoni et al. CURRENT DRUG METABOLISM
- Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma
- (2011) M. Castellarin et al. GENOME RESEARCH
- Genomic analysis identifies association of Fusobacterium with colorectal carcinoma
- (2011) A. D. Kostic et al. GENOME RESEARCH
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma
- (2010) C. Xuan et al. BLOOD
- Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients
- (2010) Vanessa Deschoolmeester et al. BMC IMMUNOLOGY
- Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil: Is it time to move forward?
- (2010) Shayna L. Showalter et al. CANCER BIOLOGY & THERAPY
- Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- (2010) Scott M. Wilhelm et al. INTERNATIONAL JOURNAL OF CANCER
- Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
- (2010) Wendy De Roock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Heterogeneous Nuclear Ribonucleoprotein H1/H2-dependent Unsplicing of Thymidine Phosphorylase Results in Anticancer Drug Resistance
- (2010) Michal Stark et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Clinical Relevance of Microsatellite Instability in Colorectal Cancer
- (2010) Albert de la Chapelle et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
- (2010) Jean-Yves Douillard et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review
- (2010) Katsuhiko Nosho et al. JOURNAL OF PATHOLOGY
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- Wnt activity defines colon cancer stem cells and is regulated by the microenvironment
- (2010) Louis Vermeulen et al. NATURE CELL BIOLOGY
- Improved, Selective, Human Intestinal Carboxylesterase Inhibitors Designed to Modulate 7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (Irinotecan; CPT-11) Toxicity
- (2009) Latorya D. Hicks et al. JOURNAL OF MEDICINAL CHEMISTRY
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunogenic death of colon cancer cells treated with oxaliplatin
- (2009) A Tesniere et al. ONCOGENE
- Local Recurrence in Mismatch Repair-Proficient Colon Cancer Predicted by an Infiltrative Tumor Border and Lack of CD8+ Tumor-Infiltrating Lymphocytes
- (2008) I. Zlobec et al. CLINICAL CANCER RESEARCH
- Predictive value of thymidylate synthase expression in advanced colorectal cancer patients receiving fluoropyrimidine-based chemotherapy: Evidence from 24 studies
- (2008) Li-Xin Qiu et al. INTERNATIONAL JOURNAL OF CANCER
- Colorectal Cancer Stem Cells Are Enriched in Xenogeneic Tumors Following Chemotherapy
- (2008) Scott J. Dylla et al. PLoS One
- Comparative lesion sequencing provides insights into tumor evolution
- (2008) S. Jones et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now